Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention...

Area of Science:

• Microbiology
• Gastroenterology
• Clinical Pharmacology

Background:

• Recurrent Clostridium difficile infections (CDI) pose a significant public health challenge with limited treatment options.
• Current antibiotic therapies show insufficient response rates for recurrent CDI.
• Microbiota-based treatments offer potential but require rigorous clinical validation for optimal dosing and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of RBX2660, a standardized microbiota-based drug, in adults experiencing recurrent CDI.
• To compare the efficacy of two doses of RBX2660 versus placebo in preventing CDI recurrence.
• To explore the efficacy of a single dose of RBX2660 and assess long-term safety.

Main Methods:

• A randomized, double-blind, placebo-controlled phase 2B trial was conducted.
• Participants with two or more CDI recurrences received either two doses of RBX2660, placebo, or one dose of RBX2660 followed by placebo.
• Efficacy was measured by the prevention of CDI recurrence over 8 weeks, with an open-label extension for participants who recurred.

Main Results:

• The primary endpoint comparing two doses of RBX2660 to placebo was not met (61% vs. 45%, P = .152).
• A single dose of RBX2660 demonstrated superiority over placebo (67% vs. 45%, P = .048).
• Overall efficacy, including open-label treatment, reached 88.8% for RBX2660 recipients, with no significant difference in adverse events.

Conclusions:

• A single administration of RBX2660 proved more effective than placebo in preventing recurrent CDI.
• These findings support the continued development of RBX2660, including a single-dose regimen, for future phase 3 trials.
• RBX2660 represents a promising microbiota-based therapeutic for managing recurrent CDI.